Wire · opportunities
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Cullinan Therapeutics and Taiho Oncology reported that their drug zipalertinib, combined with chemotherapy, improved progression-free survival by six months in a phase 3 trial for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. The data suggest a potential practice-changing treatment that may extend patient survival compared to current standards like Johnson & Johnson's Rybrevant.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Oncology founders working on EGFR-mutated lung cancer should act fast to differentiate or prepare for competition as zipalertinib shows superior progression-free survival to J&J’s Rybrevant. Regulators are in early review, which could open urgent market access or force repricing and repositioning at launch.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics